Cargando…
The anticancer drug mithramycin A sensitises tumour cells to apoptosis induced by tumour necrosis factor (TNF)
In this report we show that mithramycin considerably increases the direct cytotoxic effect of tumour necrosis factor (TNF) on tumour cells in vitro. Sensitisation to TNF-induced apoptosis was prevented by the broad caspase inhibitor zVAD-fmk, whereas overexpression of Bcl-2 had no effect. Mithramyci...
Autores principales: | , , , , , , |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2004
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2409467/ https://www.ncbi.nlm.nih.gov/pubmed/15138489 http://dx.doi.org/10.1038/sj.bjc.6601824 |
_version_ | 1782155771211939840 |
---|---|
author | Duverger, V Murphy, A-M Sheehan, D England, K Cotter, T G Hayes, I Murphy, F J |
author_facet | Duverger, V Murphy, A-M Sheehan, D England, K Cotter, T G Hayes, I Murphy, F J |
author_sort | Duverger, V |
collection | PubMed |
description | In this report we show that mithramycin considerably increases the direct cytotoxic effect of tumour necrosis factor (TNF) on tumour cells in vitro. Sensitisation to TNF-induced apoptosis was prevented by the broad caspase inhibitor zVAD-fmk, whereas overexpression of Bcl-2 had no effect. Mithramycin also potentiated cell death induced by Fas agonistic antibodies. In contrast, mithramycin reduced the percentage of cells undergoing apoptosis due to factor withdrawal. TNF-induced activation of NF-kappaB (NF-κB)-dependent gene expression was not modulated by mithramycin treatment. Concomitantly with the increased sensitivity, the protein level of the short-spliced cFLIP variant was downregulated. These results indicate that mithramycin enhances TNF-induced cell death in an NF-κB-independent manner, and suggest that the Fas-associated death domain protein plays a crucial role in the TNF-sensitising effect of mithramycin. |
format | Text |
id | pubmed-2409467 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2004 |
publisher | Nature Publishing Group |
record_format | MEDLINE/PubMed |
spelling | pubmed-24094672009-09-10 The anticancer drug mithramycin A sensitises tumour cells to apoptosis induced by tumour necrosis factor (TNF) Duverger, V Murphy, A-M Sheehan, D England, K Cotter, T G Hayes, I Murphy, F J Br J Cancer Experimental Therapeutics In this report we show that mithramycin considerably increases the direct cytotoxic effect of tumour necrosis factor (TNF) on tumour cells in vitro. Sensitisation to TNF-induced apoptosis was prevented by the broad caspase inhibitor zVAD-fmk, whereas overexpression of Bcl-2 had no effect. Mithramycin also potentiated cell death induced by Fas agonistic antibodies. In contrast, mithramycin reduced the percentage of cells undergoing apoptosis due to factor withdrawal. TNF-induced activation of NF-kappaB (NF-κB)-dependent gene expression was not modulated by mithramycin treatment. Concomitantly with the increased sensitivity, the protein level of the short-spliced cFLIP variant was downregulated. These results indicate that mithramycin enhances TNF-induced cell death in an NF-κB-independent manner, and suggest that the Fas-associated death domain protein plays a crucial role in the TNF-sensitising effect of mithramycin. Nature Publishing Group 2004-05-17 2004-04-20 /pmc/articles/PMC2409467/ /pubmed/15138489 http://dx.doi.org/10.1038/sj.bjc.6601824 Text en Copyright © 2004 Cancer Research UK https://creativecommons.org/licenses/by/4.0/This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material.If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit https://creativecommons.org/licenses/by/4.0/. |
spellingShingle | Experimental Therapeutics Duverger, V Murphy, A-M Sheehan, D England, K Cotter, T G Hayes, I Murphy, F J The anticancer drug mithramycin A sensitises tumour cells to apoptosis induced by tumour necrosis factor (TNF) |
title | The anticancer drug mithramycin A sensitises tumour cells to apoptosis induced by tumour necrosis factor (TNF) |
title_full | The anticancer drug mithramycin A sensitises tumour cells to apoptosis induced by tumour necrosis factor (TNF) |
title_fullStr | The anticancer drug mithramycin A sensitises tumour cells to apoptosis induced by tumour necrosis factor (TNF) |
title_full_unstemmed | The anticancer drug mithramycin A sensitises tumour cells to apoptosis induced by tumour necrosis factor (TNF) |
title_short | The anticancer drug mithramycin A sensitises tumour cells to apoptosis induced by tumour necrosis factor (TNF) |
title_sort | anticancer drug mithramycin a sensitises tumour cells to apoptosis induced by tumour necrosis factor (tnf) |
topic | Experimental Therapeutics |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2409467/ https://www.ncbi.nlm.nih.gov/pubmed/15138489 http://dx.doi.org/10.1038/sj.bjc.6601824 |
work_keys_str_mv | AT duvergerv theanticancerdrugmithramycinasensitisestumourcellstoapoptosisinducedbytumournecrosisfactortnf AT murphyam theanticancerdrugmithramycinasensitisestumourcellstoapoptosisinducedbytumournecrosisfactortnf AT sheehand theanticancerdrugmithramycinasensitisestumourcellstoapoptosisinducedbytumournecrosisfactortnf AT englandk theanticancerdrugmithramycinasensitisestumourcellstoapoptosisinducedbytumournecrosisfactortnf AT cottertg theanticancerdrugmithramycinasensitisestumourcellstoapoptosisinducedbytumournecrosisfactortnf AT hayesi theanticancerdrugmithramycinasensitisestumourcellstoapoptosisinducedbytumournecrosisfactortnf AT murphyfj theanticancerdrugmithramycinasensitisestumourcellstoapoptosisinducedbytumournecrosisfactortnf AT duvergerv anticancerdrugmithramycinasensitisestumourcellstoapoptosisinducedbytumournecrosisfactortnf AT murphyam anticancerdrugmithramycinasensitisestumourcellstoapoptosisinducedbytumournecrosisfactortnf AT sheehand anticancerdrugmithramycinasensitisestumourcellstoapoptosisinducedbytumournecrosisfactortnf AT englandk anticancerdrugmithramycinasensitisestumourcellstoapoptosisinducedbytumournecrosisfactortnf AT cottertg anticancerdrugmithramycinasensitisestumourcellstoapoptosisinducedbytumournecrosisfactortnf AT hayesi anticancerdrugmithramycinasensitisestumourcellstoapoptosisinducedbytumournecrosisfactortnf AT murphyfj anticancerdrugmithramycinasensitisestumourcellstoapoptosisinducedbytumournecrosisfactortnf |